Novo Nordisk A/S
NOVO-B
Rang in Aktien
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktienkurs
$39.33
Marktkapitalisierung
$173.59B
Veränderung (1 Tag)
0.25%
Veränderung (1 Jahr)
-26.34%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategorie
Healthcare
P/B-Verhältnis für Novo Nordisk A/S (NOVO-B)
P/B-Verhältnis zum February 2026 TTM: 7.11
Laut den neuesten Finanzberichten und dem Aktienkurs von Novo Nordisk A/S beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 7.11. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 19.38.
P/B-Verlauf für Novo Nordisk A/S von 2001 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 7.11 | -4.53% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 31.9092 | 348.63% |
US
|
|
| 7.3138 | 2.83% |
US
|
|
| -84.6033 | -1,289.48% |
US
|
|
| 8.6873 | 22.14% |
US
|
|
| 8.4776 | 19.19% |
CH
|
